TABLE 1 INTERNATIONAL DISEASE CLASSIFICATION CODES AND DESCRIPTION OF CANCER DIAGNOSES
TABLE 2 LAMEA ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES, (2012)
TABLE 3 LIST OF BIOLOGICAL AND TARGETED DRUGS WITH THEIR REVENUE IN 2013 ($MILLION)
TABLE 4 LIST OF COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF CANCER DRUGS
TABLE 5 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2014 2021 ($MILLION)
TABLE 6 LAMEA CHEMOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 7 LAMEA TARGETED THERAPY DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 8 LAMEA IMMUNOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 9 LAMEA HORMONAL THERAPY DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 10 LAMEA OTHER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 11 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY CANCER TYPES, 2014 2021 ($MILLION)
TABLE 12 LAMEA BLOOD CANCER MARKET, 2014 2021 ($MILLION)
TABLE 13 LAMEA BREAST CANCER MARKET, 2014 2021 ($MILLION)
TABLE 14 LAMEA GASTROINTESTINAL CANCER MARKET, 2014 2021 ($MILLION)
TABLE 15 LAMEA PROSTATE CANCER MARKET, 2014 2021 ($MILLION)
TABLE 16 LAMEA RESPIRATORY/LUNG CANCER MARKET, 2014 2021 ($MILLION)
TABLE 17 LAMEA SKIN CANCER MARKET, 2014 2021 ($MILLION)
TABLE 18 LAMEA OTHER CANCER MARKET, 2014 2021 ($MILLION)
TABLE 19 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY COUNTRIES, 2014 2021 ($MILLION)
TABLE 20 BRAZIL ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 21 ARGENTINA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 22 NIGERIA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 23 SOUTH AFRICA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 24 IRAQ ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 25 IRAN ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 26 ALGERIA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 27 SAUDI ARABIA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 28 EGYPT ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 29 EGYPT ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)
TABLE 30 AMGEN INC. SNAPSHOT
TABLE 31 ASTRAZENECA SNAPSHOT
TABLE 32 ROCHE DIAGNOSTICS SNAPSHOT
TABLE 33 ROCHE DIAGNOSTICS OPERATING SEGEMENTS
TABLE 34 GLAXOSMITHKLINE PLC SNAPSHOT
TABLE 35 GLAXOSMITHKLINE PLC OPERATING SEGEMENTS
TABLE 36 MERCK & COMPANY SNAPSHOT
TABLE 37 MERCK & CO. OPERATING SEGEMENTS
TABLE 38 NOVARTIS AG SNAPSHOT
TABLE 39 NOVARTIS AG OPERATING SEGEMENTS
TABLE 40 ABBVIE INC. SNAPSHOT
TABLE 41 SANOFI SNAPSHOTS
TABLE 42 SANOFI OPERATING SEGEMENTS
TABLE 43 EIMC UNITED PHARMA SNAPSHOTS
TABLE 44 ACTAVIS CORPORATION SNAPSHOTS
LIST OF FIGURE
FIG. 1 TOP FACTORS IMPACTING ANTI-CANCER DRUGS MARKET (2014-2021)
FIG. 2 TOP INVESTMENT POCKETS OF ONCOLOGY/ANTI-CANCER DRUGS MARKET (2014)
FIG. 3 TOP WINNING STRATEGIES FOR GLOBAL CANCER DRUG MARKET (2011-2015)
FIG. 4 TOP WINNING STRATEGIES BY SUBTYPE (2011-2015)
FIG. 5 PERCENTAGE (%) OF ALL NEW CANCERS CASES DIAGNOSED IN 2012
FIG. 6 LAMEA CHEMOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)
FIG. 7 LAMEA TARGETED THERAPY DRUGS MARKET, 2014 2021 ($MILLION)
FIG. 8 LAMEA IMMUNOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)
FIG. 9 LAMEA HORMONAL THERAPY DRUGS MARKET, 2014 2021 ($MILLION)
FIG. 10 LAMEA OTHER DRUGS MARKET, 2014 2021 ($MILLION)
FIG. 11 LAMEA BLOOD CANCER DEATH RATE (PER 100,000), (2014)
FIG. 12 LAMEA BLOOD CANCER MARKET, 2014 2021 ($MILLION)
FIG. 13 LAMEA BREAST CANCER DEATH RATE (PER 100,000), 2014
FIG. 14 LAMEA BREAST CANCER MARKET, 2014 2021 ($MILLION)
FIG. 15 LAMEA GASTROINTESTINAL CANCER DEATH RATE (PER 100,000), 2014
FIG. 16 LAMEA GASTROINTESTINAL CANCER MARKET, 2014 2021 ($MILLION)
FIG. 17 LAMEA PROSTATE CANCER DEATH RATE (PER 100,000), 2014
FIG. 18 LAMEA PROSTATE CANCER MARKET, 2014 2021 ($MILLION)
FIG. 19 LAMEA RESPIRATORY/LUNG CANCER DEATH RATE (PER 100,000), 2014
FIG. 20 LAMEA RESPIRATORY/LUNG CANCER MARKET, 2014 2021 ($MILLION)
FIG. 21 LAMEA SKIN CANCER DEATH RATE (PER 100,000), 2014
FIG. 22 LAMEA SKIN CANCER MARKET, 2014 2021 ($MILLION)
FIG. 23 LAMEA OTHER CANCER MARKET, 2014 2021 ($MILLION)
FIG. 24 AMGEN INC. REVENUE BY GEOGRAPHY (2014)
FIG. 25 AMGEN INC. REVENUE BY PRODUCT PORTFOLIO (2014)
FIG. 26 SWOT ANALYSIS OF AMGEN INC.
FIG. 27 FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 28 FINANCIAL REVENUES BY YEAR, 2014 ($MILLION)
FIG. 29 SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 30 ROCHE DIAGNOSTICS BY BUSINESS UNITS (2014)
FIG. 31 SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIG. 32 GLAXOSMITHKLINE PLC REVENUE BY GEOGRAPHY (2014)
FIG. 33 GLAXOSMITHKLINE PLC REVENUE BY BUSINESS SEGMENTS (2014)
FIG. 34 SWOT ANALYSIS OF GLAXOSMITHKLINE PLC
FIG. 35 MERCK & CO. REVENUE BY GEOGRAPHY (2014)
FIG. 36 SWOT ANALYSIS OF MERCK & COMPANY
FIG. 37 NOVARTIS AG REVENUE BY GEOGRAPHY (2014)
FIG. 38 NOVARTIS AG REVENUE BY BUSINESS SEGMENTS (2014)
FIG. 39 SWOT ANALYSIS OF NOVARTIS AG
FIG. 40 NET SALES REVENUES OF ABBVIE BY GEOGRAPHY, 2014 ($MILLION)
FIG. 41 SWOT ANALYSIS OF ABBVIE
FIG. 42 SANOFI REVENUE BY GEOGRAPHIES (2014)
FIG. 43 SANOFI REVENUE BY BUSINESS SEGMENTS (2014)
FIG. 44 SWOT ANALYSIS OF SANOFI
FIG. 45 SWOT ANALYSIS OF EUP
FIG. 46 ACTAVIS CORPORATION REVENUE BY PRODUCT SALES (2014)
FIG. 47 SWOT ANALYSIS OF ACTAVIS PLC